{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T03:44:03Z","timestamp":1775015043412,"version":"3.50.1"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[1997,3,1]],"date-time":"1997-03-01T00:00:00Z","timestamp":857174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1997,3]]},"abstract":"<jats:p>Voriconazole, a new azole antifungal agent, showed potent activity against clinical isolates of Aspergillus spp. in vitro. For A. fumigatus, the MIC range was &lt; 0.03 to 0.5 microgram\/ml and the MIC at which 90% of isolates are inhibited was 0.25 microgram\/ml. In an experimental model of invasive pulmonary aspergillosis which mimics infection in humans, oral voriconazole at dosages of 30 mg\/kg of body weight per day significantly delayed or prevented mortality.<\/jats:p>","DOI":"10.1128\/aac.41.3.696","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:28:15Z","timestamp":1539044895000},"page":"696-698","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":118,"title":["Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis"],"prefix":"10.1128","volume":"41","author":[{"given":"M","family":"Murphy","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. murphym@mskcc.org"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E M","family":"Bernard","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. murphym@mskcc.org"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Ishimaru","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. murphym@mskcc.org"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. murphym@mskcc.org"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.41.3.696","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.41.3.696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:11:41Z","timestamp":1645474301000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.41.3.696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,3]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,3]]}},"alternative-id":["10.1128\/AAC.41.3.696"],"URL":"https:\/\/doi.org\/10.1128\/aac.41.3.696","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,3]]},"assertion":[{"value":"1997-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}